Who Paid My Doc
Andrew Phillips
Optometrist, Low Vision Rehabilitation Arcadia, CA Doctor of Optometry
NPI 1366522427 CMS profile 288450
301 W Huntington Dr, Suite 605, Arcadia, CA 91007
General payments
$1,454
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Andrew Phillips of Arcadia, CA is reported in the CMS Open Payments database as having received $1,454 across 35 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 82nd percentile of Optometrist, Low Vision Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $387 | 7 | |
| 2023 | General | $144 | 1 | |
| 2022 | General | $385 | 9 | |
| 2021 | General | $142 | 4 | |
| 2020 | General | $56 | 3 | |
| 2019 | General | $340 | 11 |
Beside peers
- Andrew Phillips
- Optometrist, Low Vision Rehabilitation median
- Middle half of Optometrist, Low Vision Rehabilitation
- National median
In program year 2025, general payments to Andrew Phillips were reported at $387. Among 89 Optometrist, Low Vision Rehabilitation profiles paid that year, the median was $150 and the middle half received between $50 and $382.
Show as a table
| Year | Andrew Phillips | Optometrist, Low Vision Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $340 | $126 | $62–$303 | $163 |
| 2020 | $56 | $57 | $19–$124 | $114 |
| 2021 | $142 | $137 | $48–$277 | $132 |
| 2022 | $385 | $135 | $53–$282 | $149 |
| 2023 | $144 | $141 | $52–$361 | $160 |
| 2024 | $0 | $146 | $75–$336 | $164 |
| 2025 | $387 | $150 | $50–$382 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
1,474
Drug cost
$55,788
Branded share of claims
18.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lumigan Bimatoprost | Brand | 36 | $16,739 | |
| Latanoprost | Generic | 549 | $7,936 | |
| Brinzolamide | Generic | 19 | $5,103 | |
| Timolol Maleate | Generic | 214 | $4,279 | |
| Simbrinza Brinzolamide/Brimonidine Tart | Brand | 17 | $4,154 | |
| Loteprednol Etabonate | Generic | 33 | $4,144 | |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | Brand | 150 | $2,996 | |
| Brimonidine Tartrate | Generic | 115 | $2,875 | |
| Prednisolone Acetate | Generic | 87 | $2,721 | |
| Fluorometholone | Generic | 28 | $1,613 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$350,619
Medicare patients
1,246
Services billed
4,405
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 48% | |
| Diabetes | 40% | |
| Ischemic heart disease | 25% | |
| Chronic kidney disease | 22% | |
| Atrial fibrillation | 20% | |
| Cancer | 20% | |
| Osteoporosis | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, aflibercept, 1 mg J0178 | Office | 12 | 46 | $30,625 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
35 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Optometrist, Low Vision Rehabilitation in California
Lyly Ung
Optometrist, Low Vision Rehabilitation · San Francisco, CA
Joseph Laya
Optometrist, Low Vision Rehabilitation · Redding, CA
Shirley Hong
Optometrist, Low Vision Rehabilitation · Rowland Heights, CA
Linda Yee
Optometrist, Low Vision Rehabilitation · San Jose, CA
Grace Jeng
Optometrist, Low Vision Rehabilitation · Oakland, CA
Tiffany Chan
Optometrist, Low Vision Rehabilitation · San Francisco, CA
Related records
Optometrist, Low Vision Rehabilitation in California
Practitioners in the same specialty and state, ranked by reported value.
All Optometrist, Low Vision Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.